![Diana Brainard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 135 908 $ al 31/08/2026
Diana M.
Brainard is currently an Independent Director at Nektar Therapeutics since 2021 and an Independent Director at Affinia Therapeutics, Inc. since 2022.
Formerly, served as Chief Executive Officer & Director at AlloVir, Inc. from 2021 to 2024, Senior VP-HIV & Emerging Viral Infections at Gilead Sciences, Inc. from 2018 to 2021, and Partner at MPM BioImpact LLC.
Education includes an undergraduate degree from Brown University in 1992 and a doctorate from Tulane University School of Medicine in 1997.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NEKTAR THERAPEUTICS 0,01 % | 06/04/2026 | 1.904 ( 0,01 % ) | 135 908 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NEKTAR THERAPEUTICS | Director/Miembro de la Junta | 11/11/2021 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Director/Miembro de la Junta | 08/03/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| ALLOVIRPAR | Director Ejecutivo | 19/12/2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Inversor de Capital Privado | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 7 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Tulane University School of Medicine
 Tulane University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AlloVir, Inc.
 AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
